Deprenyl - Anti-Aging Drug Proven Effective in Dogs

Key Takeaways

• Meta-analysis of 22 experiments shows moderate lifespan increase (SMD 0.68).
• Higher doses and older start age amplify L‑deprenyl’s effect.
• Reanalysis of canine study finds no significant survival benefit after adjustment.
• Safety data suggest low‑dose L‑deprenyl can be combined with SSRIs.
• Ongoing human trials will test translatability to older adults.

Pulse Analysis

L‑deprenyl, marketed as selegiline, has been a mainstay in Parkinson’s therapy for decades, yet its reputation as a potential anti‑aging agent has lingered in scientific circles. The drug’s mechanism—selective inhibition of monoamine oxidase‑B—boosts brain dopamine and may influence mitochondrial function, a pathway often linked to longevity. As the anti‑aging market expands, investors and biotech firms watch repurposed compounds like L‑deprenyl for cost‑effective pathways to extend healthspan, especially given its established safety profile and regulatory approval.

The recent meta‑analysis aggregates 22 controlled lifespan studies spanning 27 years, eight rodent strains, four species and six dosage regimens. Results reveal a moderate effect size (SMD 0.68) that reaches statistical significance, but heterogeneity is high, indicating that outcomes differ markedly across experiments. Meta‑regression pinpoints two key moderators: higher daily doses and initiation at later ages both correlate with larger lifespan gains. Notably, when the lone canine trial is re‑examined with adjustments for enrollment age and sex, the previously reported survival benefit vanishes, underscoring the fragility of the evidence in larger mammals.

For stakeholders, the analysis delivers both opportunity and caution. Low‑dose L‑deprenyl appears safe to co‑administer with common SSRIs, mitigating concerns about serotonin syndrome, which broadens its potential use in older populations already on antidepressants. However, the heterogeneous pre‑clinical data demand rigorous human trials. Ongoing studies, such as a 1 mg/day rasagiline trial in prodromal Parkinson’s patients, will provide critical insight into whether the modest rodent benefits translate into meaningful health‑span extensions for seniors, shaping future investment and therapeutic strategies.